Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.
Sarat Chandarlapaty, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, highlights responses to amcenestrant (SAR439859) and palbociclib (Ibrance) in patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial (NCT03284957).
The combination was safe, with investigators having observed the same adverse effect profile that was seen with the individual agents, Chandarlapaty says. There was no synergistic effect by putting the 2 agents together, with regard to safety. The combination was also active, with 74.3% of evaluable patients experiencing clinical benefit, he says.
Activity was observed in patients who had received prior treatment with hormone therapy, prior chemotherapy, and in those who had evidence for an activating mutation of the ER. This included even Y537S, the most activating mutation, Chandarlapaty says. These findings suggest that the combination is a broadly active treatment regimen, Chandarlapaty concludes.